Categories
Tags
Authors: Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R et al. PMID: 36001529 PMCID: PMC9454652 DOI: 10.1056/NEJMoa2204919 Abstract Background: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir, Omicron
Authors: Gupta K, Strymish J, Stack G, Chamess M DOI: https://doi.org/10.21203/rs.3.rs-1588371/v1 Abstract Initiation of NM/R treatment on Day 0 in a 71-year-old vaccinated and boosted male resulted in rapid resolution of COVID-19 symptoms followed one week later by the development of typical cold symptoms. SARS-CoV-2 viral load fluctuated in parallel with symptoms, with two distinct [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir, SARS-CoV-2
Authors: Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W DOI: 10.1056/NEJMoa2118542 Abstract BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir